Clinical Trial Update: Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension Vaccine CYT006-AngQb [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update reporting safety and tolerability, pharmacodynamic effects and preliminary evidence of efficacy for the anti-hypertension vaccine CYT006-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• CYT006-AngQb

Snippet

Sponsor: Cytos Biotechnology AG | Conditions: Essential Hypertension | Phase 1, Phase 2 | Status: COMPLETED